Enovix (NASDAQ:ENVX) Issues Q3 2026 Earnings Guidance

Enovix (NASDAQ:ENVXGet Free Report) updated its third quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -0.170–0.130 for the period, compared to the consensus estimate of -0.150. The company issued revenue guidance of $9.0 million-$10.0 million, compared to the consensus revenue estimate of $10.3 million.

Enovix Price Performance

Shares of NASDAQ ENVX traded down $0.10 during midday trading on Wednesday, reaching $4.73. 8,815,678 shares of the company traded hands, compared to its average volume of 6,373,630. Enovix has a 12 month low of $3.67 and a 12 month high of $14.21. The company has a debt-to-equity ratio of 2.14, a quick ratio of 10.65 and a current ratio of 10.97. The stock’s 50-day simple moving average is $5.54 and its 200-day simple moving average is $5.92. The firm has a market cap of $1.03 billion, a PE ratio of -5.70 and a beta of 2.32.

Enovix (NASDAQ:ENVXGet Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. The business had revenue of $9.02 million for the quarter, compared to analyst estimates of $8.43 million. Enovix had a negative net margin of 499.64% and a negative return on equity of 64.28%. Enovix has set its Q3 2026 guidance at -0.170–0.130 EPS. As a group, equities analysts anticipate that Enovix will post -0.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ENVX has been the subject of several recent analyst reports. Benchmark dropped their price objective on shares of Enovix from $25.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Oppenheimer reduced their target price on Enovix from $24.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. JPMorgan Chase & Co. lowered Enovix from a “neutral” rating to an “underweight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised Enovix from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, TD Cowen cut their price objective on Enovix from $7.00 to $5.50 and set a “hold” rating for the company in a research report on Friday, July 24th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Enovix has an average rating of “Hold” and a consensus target price of $12.50.

View Our Latest Stock Analysis on Enovix

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ENVX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enovix by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock valued at $722,000 after acquiring an additional 4,780 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in Enovix by 10.4% during the first quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock worth $193,000 after acquiring an additional 2,481 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Enovix by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock valued at $8,351,000 after acquiring an additional 449,934 shares during the period. Caxton Associates LLP acquired a new position in Enovix in the first quarter valued at about $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Enovix by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock worth $2,628,000 after acquiring an additional 55,676 shares in the last quarter. Institutional investors and hedge funds own 50.92% of the company’s stock.

Enovix Company Profile

(Get Free Report)

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.

Featured Stories

Receive News & Ratings for Enovix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovix and related companies with MarketBeat.com's FREE daily email newsletter.